• NUCLIDIUM closes EUR 84 million Series B financing to advance the clinical development of its copper-based radiopharmaceutical platform led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, VIVES Partners, NRW.BANK, and HighLight Capital, with existing investors
   
• Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based radiopharmaceuticals with initial clinical data presented at SNMMI 2025
   
• Alongside Tony Rosenberg, who recently joined as Chairman of the Board of Directors, David Meek joins as a new independent member of the Board; Oliver Sartor, MD and Bela Denes, MD join as Scientific Advisors
   
• NUCLIDIUM is the tenth investment of the Kurma Growth Opportunities Fund dedicated to scale-up promising European life sciences leaders

Paris, France / Munich, Germany, July 10, 2025 - Kurma Partners announces, that NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform successfully closed its Series B financing round, raising CHF 79 million (EUR 84 million). The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, VIVES Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors. The proceeds will be used to advance the clinical development of NUCLIDIUM’s Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network.

NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. Diagnostic results from initial clinical trials in these indications show superior lesion detection and higher tumor-to-background ratios compared with clinically approved tracers. Initial data were recently presented at SNMMI 2025 by Dr. Gary Ulaner, MD, PhD, highlighting a favorable safety profile and potentially improved imaging performance of 61Cu-NuriPro™ compared to current PET imaging standards, suggesting strong clinical promise and broader potential for 61Cu/67Cu theranostic pairing. Early therapeutic data from the two lead compounds, NuriPro™ and TraceNET™, show strong tumor-to-background ratios in metastatic prostate cancer and neuroendocrine tumors including breast cancer.

With this financing, NUCLIDIUM will continue expanding its worldwide production and manufacturing network for diagnostics and therapeutics, growing its international team, and strengthening strategic collaborations with hospitals and academic centers, initially across Europe and North America.
In conjunction with the financing round, Daniel Parera, MD, Partner at Kurma Partners, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Partner Life Sciences at Neva SGR, will join NUCLIDIUM’s Board of Directors.

Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM commented: “NUCLIDIUM is entering the next clinical phases with its lead compounds to diagnose and treat metastatic prostate, neuroendocrine tumors and breast cancer. Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care delivery and waste management, making these therapies more accessible worldwide. Our groundbreaking next generation copper theranostic platform also allows us to rapidly develop new targets across a wider range of cancers, particularly those highly relevant to women’s health”. 

Tony Rosenberg, chairman of the NUCLIDIUM board commented: “This significant Series B financing reflects the confidence of our investors in NUCLIDIUM’s vision and the transformative potential for the diagnostic and therapeutic industry in oncology and nuclear medicine. With this backing, we are positioned to accelerate clinical development, broaden patient access globally, and reinforce our commitment to innovation in precision oncology. I am delighted to welcome our new board and advisory members, whose deep expertise will further strengthen NUCLIDIUM’s leadership in radiopharmaceuticals.” 

Daniel Parera, MD, Partner at Kurma Partners commented: “NUCLIDIUM’s platform stands out in a rapidly evolving field and will change how radiotheranostic care is delivered. Following our recent investment in isotope producer PanTera, this new growth investment reflects our commitment to strengthen the European ecosystem by scaling NUCLIDIUM’s copper-based platform as the next generation radiotheranostics.”